

Veeda's Commitment to 505(b)(2):

Your Dedicated Partner to Accelerate New Drug Applications



Features of the 505(b)(2) Pathway Driving Industry's Interest

	Studies	Market exclusivity	Timing for Approval	Cost of Drug Development	Clinical trials, Non-clinical / Toxicology data
505(b)(1)	Full	5 years	8–15 years	\$500 m – 2b	Yes
505(b)(2)	Partial	3–5 years	2–5 years	\$3 m – 7 m	Maybe

Key Challenges Associated with Traditional Pathway

- Need for sophisticated planning and development process
- Need for expertise knowledge in determining measurements and studies required to demonstrate therapeutic equivalence
- Difficult to establish equivalence, safety and efficacy endpoints of therapy
- Challenging time-consuming and expensive to develop
- Lack of clear regulatory guidelines for approval
- Identification of targeted markets and indications to address unmet patient need

USFDA Approvals Through the 505(b)(2) Pathway as of May 2024: Key Drugs

- Irinotecan Liposomal
- Budesonide Oral Suspension
- Iloprost
- Clobetasol Propionate 0.05%
- Macitentan/Tadalafil

- Risperidone Extended-Release Injection
- Mycophenolate Mofetil Oral Suspension
- Naloxone Hydrochloride Nasal Spray
- Diazepam Buccal Film



Veeda Group's Capabilities in Supporting 505(b)(2) Applications

Pre-Clinical Studies	Clinical Studies		
In vitro studies	Single & multiple dose BA/BE		
In vitro dose dumping studies	Dose proportionality		
In vitro PD studies	Pharmacokinetics/Pharmacodynamics		
In vivo studies	Food effect		
	Safety/ efficacy studies		
	Drug Interaction		
	 Single Ascending Dose/ Multiple Ascending Dose 		

Proficiency in More Than 10 Therapy Areas Including Psychiatry, Endocrinology, Respiratory, Dermatology and others


Veeda Group's proficiency in Navigating Regulatory Approvals through 505(b)(2) Pathways:

Successfully Executed 45 Studies


Completed 14 Complex Studies

Enrolled 1300+ Volunteers

Collaborated with 25+ Global Sponsors



Wide Experience across Different Formulations:



Studies Successfully Submitted to Global Regulatory Bodies such as: ANVISA, Canada, DCGI, USFDA, NPRA

Veeda Group Advantage

- Skilled personnel with focus on Continuous Professional Development
- High Customer Centricity and Satisfaction
- Extensive Scientific Competence to service a Diverse client base
- One of the largest Independent Full Service CROs in India
- Robust Quality & Regulatory Compliance
- One stop solution for complex studies







www.veedalifesciences.com

